CD264 TNFRSF10D (tumor necrosis factor receptor superfamily member 10D, decoy with truncated death domain), TNF-R, TRUNDD, TRAIL-R4, DcR2
Molecule TypeAntigen ExpressionMolecular Weight
Min / Max
Non-lineage Restricted Molecule
Type 1 glycoprotein
Broad
Macrophage
Lung
Liver
Kidney
Colon
Small intestine
Ovary
Prostate
Pancreas
Thymus
Spleen
Heart
Placenta
Monocyte
Granulocyte
Lymphocyte
NK Cell
T Lymphocyte
B Lymphocyte
Peripheral blood
Testis
Leukocyte
35 / 35

Expression
CD264 is expressed on T and B lymphocytes, peripheral blood lymphocytes, NK cells, macrophages, monocytes and granulocytes.  Expression is on broad cells but is at a low level in most tissues and negative in most tumor tissues.  There is wide expression in fetal kidney, lung, liver and in adult testis and liver. Expression is also in peripheral blood leukocytes, colon, small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta, and heart.

Structure
MOLECULAR FAMILY NAME: Belongs to the tumor necrosis factor receptor family.

CD264 is a single-pass type-1 331 aa glycoprotein.  It contains a 21 aa signal sequence, an 156 aa extracellular domain which contains 3 TNFR cysteine-rich repeats and 2 potential N-linked glycosylation sites, a 21 aa transmembrane domain and an 154 aa C-terminal sequence cytoplasmic domain containing a nonfunctional truncated death domain. 

MOLECULAR MASS

POST-TRANSCRIPTIONAL MODIFICATION: No information.

POST-TRANSLATIONAL MODIFICATION: No information. 

Ligands
LIGANDS AND MOLECULE ASSOCIATED WITH CD264

CD264 binds CD253 (TRAIL).

Function
CD263 is a membrane receptor for the cytotoxic ligand CD253 and is thought to act as a decoy receptor.   It does not have a cytoplasmic death domain, and therefore is not capable of inducing apoptosis and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis by competing for binding with other TRAIL receptors.  Unlike other TRAIL receptors, CD261 (TRAIL-R1) and CD262 (TRAIL-R2), CD264 (TRAIL-R4) lacks the death domain and cannot transmit apoptotic signal to the cell upon TRAIL binding.  Normal tissues that express CD263 and CD264 are resistant to TRAIL-induced apoptosis even in the presence of apoptoic signaling receptors CD261 and CD262.  The role of CD264 in malignant tissue is unclear and various studies reveal conflicting results as to its importance in the control of TRAIL-mediated cell death in tumors.
BIOCHEMICAL ACTIVITY: No information.

DISEASE RELEVANCE AND FUNCTION OF CD264 IN INTACT ANIMAL: No information.

Comments
MOLECULAR INTERACTIONS-
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD264: No information.

SUBSTRATES: No information.

ENZYMES WHICH MODIFY CD264: No information.

ADDITIONAL INSIGHTS

For further information see Degli-Esposti, M. A. et al (1997) Immunity 7: 813-820.


Database accession numbers
AnimalPIRSWISSPROTEMGBL/GENBANK
 
HumanEntrezgene 8793Q9UBN6
Antibodies

Revised June 25, 2008


Contact us: Webmaster |  509-335-9515 | Accessibility | Copyright | Policies
College of Veterinary Medicine Washington State University, Pullman, WA, 99164-7010 USA
Copyright 1995-2003 Washington State University